IL17A and inflammatory bowel disease: In conclusion, while we did not find an increased risk for IBD after initiation of anti-IL-17 directed therapies, close monitoring of symptoms and biomarkers which may suggest IBD before and during treatment with SEC, IXE, and BRO appears reasonable.